MarketCap
Facebook
X
TelegramAnnual report 2024
added 04-25-2026
Nymox Pharmaceutical Corporation ROA Ratio 2011-2026 | NYMX
Annual ROA Ratio Nymox Pharmaceutical Corporation
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | -868.81 | -270.27 | -239.79 | -131.18 | -1371.71 | -637.24 | -2512.37 | -322.94 | -507.93 | -434.82 | -151.4 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -131.18 | -2512.37 | -677.13 |
Quarterly ROA Ratio Nymox Pharmaceutical Corporation
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -821.65 | -907.29 | -582.1 | -641.92 | -313.09 | -385.49 | -372.26 | -591.11 | -428.65 | -461.63 | -422.21 | -197.6 | -111.36 | -169.77 | -195.19 | -187.95 | -384.47 | -384.47 | -326.07 | -279.25 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -111.36 | -907.29 | -408.18 |
ROA Ratio of other stocks in the Biotechnology industry
| Issuer | ROA Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
FSD Pharma
HUGE
|
-241.53 | - | 5743.5 % | $ 69.7 M |  Canada |
 |
MorphoSys AG
MOR
|
-20.13 | - | 2.43 % | $ 254 M |  Germany |
 |
Happiness Biotech Group Limited
HAPP
|
-22.19 | - | 1.35 % | $ 17.8 M |  China |
 |
Amphastar Pharmaceuticals
AMPH
|
6.02 | $ 16.89 | -2.37 % | $ 789 M |  USA |
 |
AgeX Therapeutics
AGE
|
-275.96 | - | -10.17 % | $ 12.2 K | USA |
 |
Compugen Ltd.
CGEN
|
22.57 | $ 2.85 | -5.94 % | $ 266 M |  Israel |
 |
I-Mab
IMAB
|
7.43 | - | - | $ 866 M | China |
 |
Coherus BioSciences
CHRS
|
65.04 | $ 1.58 | -3.37 % | $ 185 M | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
3.33 | - | - | $ 40.3 B | USA |
 |
Biophytis SA
BPTS
|
-89.6 | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
23.87 | - | 2.54 % | $ 160 B | France |
 |
AstraZeneca PLC
AZN
|
8.97 | - | - | $ 96.9 B |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-53.39 | - | -1.52 % | $ 24.7 M | USA |
 |
Arcturus Therapeutics Holdings
ARCT
|
-24.26 | $ 7.46 | -4.73 % | $ 204 M | Israel |
 |
Athira Pharma
ATHA
|
-114.6 | - | - | $ 269 M | USA |
 |
BiondVax Pharmaceuticals Ltd.
BVXV
|
-40.14 | - | 0.74 % | $ 768 M | Israel |
 |
Galera Therapeutics
GRTX
|
2071.28 | - | -32.59 % | $ 7.61 M | USA |
 |
Eton Pharmaceuticals
ETON
|
-4.99 | $ 29.73 | -0.77 % | $ 800 M | USA |
 |
Exelixis
EXEL
|
27.51 | $ 50.09 | -1.98 % | $ 13.6 B | USA |
 |
Midatech Pharma plc
MTP
|
-35.12 | - | -18.52 % | $ 27.3 M | Britain |
 |
Fortress Biotech
FBIO
|
19.94 | $ 2.47 | 7.39 % | $ 68.9 M | USA |
|
Forte Biosciences
FBRX
|
-83.81 | $ 22.53 | -5.97 % | $ 292 M | USA |
 |
Fennec Pharmaceuticals
FENC
|
-13807.03 | $ 9.51 | 2.92 % | $ 272 M | USA |
 |
AbCellera Biologics
ABCL
|
-10.79 | $ 4.03 | -8.52 % | $ 1.2 B | Canada |
 |
Autolus Therapeutics plc
AUTL
|
-48.81 | $ 1.57 | -1.26 % | $ 418 M | Britain |
 |
Институт стволовых клеток человека
ISKJ
|
4.82 | - | - | - |  Russia |
 |
BioNTech SE
BNTX
|
-5.17 | $ 88.94 | -3.32 % | $ 21.5 B | Germany |
 |
Checkmate Pharmaceuticals
CMPI
|
-77.89 | - | - | $ 231 M | USA |
 |
Galectin Therapeutics
GALT
|
-157.87 | $ 2.22 | -5.74 % | $ 142 M | USA |
 |
Gilead Sciences
GILD
|
14.42 | $ 129.56 | -1.9 % | $ 161 B | USA |
 |
Genmab A/S
GMAB
|
17.12 | $ 26.79 | -0.41 % | $ 1.73 B |  Danmark |
 |
Advaxis
ADXS
|
-289.96 | - | -9.65 % | $ 45.9 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-103.3 | $ 3.36 | -5.62 % | $ 5.53 M | Israel |
 |
Aeterna Zentaris
AEZS
|
-48.33 | - | 5.93 % | $ 314 M | Canada |
 |
Aeglea BioTherapeutics
AGLE
|
-19.95 | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
-35.55 | - | - | $ 867 M | Germany |
 |
Applied Genetic Technologies Corporation
AGTC
|
-27.57 | - | - | $ 26.5 M | USA |
 |
Grifols, S.A.
GRFS
|
0.99 | $ 7.67 | -1.6 % | $ 5.21 B |  Spain |
 |
AIkido Pharma
AIKI
|
-19.87 | - | 1.93 % | $ 17.4 M | USA |
|
Enlivex Therapeutics Ltd.
ENLV
|
53.1 | $ 0.72 | -1.76 % | $ 32.9 M | Israel |
 |
Akero Therapeutics
AKRO
|
-30.52 | - | - | $ 3.67 B | USA |
 |
Esperion Therapeutics
ESPR
|
-4.87 | $ 3.13 | 0.32 % | $ 651 M | USA |
 |
Aptose Biosciences
APTO
|
-254.37 | - | -45.71 % | $ 1.2 M | Canada |
 |
Aptinyx
APTX
|
-97.25 | - | -39.0 % | $ 4.57 M | USA |
 |
Akouos
AKUS
|
-31.09 | - | 0.23 % | $ 488 M | USA |
 |
Albireo Pharma
ALBO
|
-11.27 | - | -0.23 % | $ 916 M | USA |
 |
AlloVir
ALVR
|
-35.68 | - | 4.14 % | $ 49.1 M | USA |
 |
Allakos
ALLK
|
-76.23 | - | - | $ 28.6 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
-3.73 | $ 21.66 | 0.42 % | $ 2.76 B | USA |
 |
Allena Pharmaceuticals
ALNA
|
-140.01 | - | 3.16 % | $ 1.9 M | USA |